In this report, Technavio covers the present scenario and growth prospects of the global protein therapeutics market for 2017-2021 (base year: 2016; forecast year:2021). To calculate the market size, the report considers revenue generated from the sales of branded and biosimilar drugs used for the treatment of various diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

PART 01: Executive summary 7

Alternate therapies hinder the growth possibilities of approved therapies 16

PART 02: Scope of the report 18

Market overview 18

Assumptions 19

Top-vendor offerings 20

PART 03: Market research methodology 23

Research methodology 23

Economic indicators 23

PART 04: Introduction 24

Key market highlights 24

Highlights 24

PART 05: Market landscape 26

Market overview 26

Five forces analysis 33

PART 06: Market segmentation by product type 34

Global mAbs market 35

Global human insulin market 40

Global clotting factors market 45

Global EPO market 49

Global human growth hormone market 52

PART 07: Market segmentation by therapy area 55

Metabolic and endocrine disorders 55

Hematopoiesis 56

Fertility 56

Cancer 56

Autoimmune diseases 56

Infectious diseases 56

Protein vaccine 57

PART 08: Market segmentation by protein function 58

Enzymatic and regulatory activity 58

Special targeting activity 59

Vaccines 60

Protein diagnostics 60

PART 09: Geographical segmentation 61

Protein therapeutics market in Americas 63

Protein therapeutics market in EMEA 67

Protein therapeutics market in APAC 70

PART 10: Market drivers 73

Increased demand for mAbs 73

Development of novel therapies using innovative

technologies 74

Availability of favorable reimbursement policies 77

PART 11: Impact of drivers 78

PART 12: Market challenges 79

Complexities in manufacturing, storage conditions,

distribution policies, and high cost 79

Complicated regulatory framework 80

Alternate therapies loom large 82

PART 13: Impact of drivers and challenges 85

PART 14: Market trends 86

Emergence of next-generation biologics 86

Advent of biosimilars expected to improve the treatment

rates 89

Strategic alliances further boost the R&D efforts 90

PART 15: Vendor landscape 92

Competitive scenario 92

Market share analysis 2016 93

Other prominent vendors 103

PART 16: Key vendor analysis 108

F. Hoffmann-La Roche 108

Novo Nordisk 110

Amgen 113

AbbVie 115

Johnson & Johnson 119

Merck 121

PART 17: Appendix 125

List of abbreviations 125

PART 18: Explore Technavio 127